Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT00461708
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT00461058
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT00461006
ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.
Phase 4
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00461266
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 133
- Registration Number
- NCT00460941
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2008-06-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00460850
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT00454636
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2011-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 111
- Registration Number
- NCT00454246
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2252
- Registration Number
- NCT00451906
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2296
- Registration Number
- NCT00448591
© Copyright 2024. All Rights Reserved by MedPath